Phase 2 N=3 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: PFS
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=93 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: Confirmed Response Rate — 10; 14 percentage of participants
Phase 2 N=36 Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Phase 2 N=32 Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Carcinoid Tumor · Metastatic Carcinoid Tumor · Neuroendocrine Neoplasm
Primary: PFS — 11 months
Phase 2 N=40 Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
Neuroendocrine Tumors
Primary: 12-month Progression Free Survival (PFS) — 64.7 percentage of participants w/ 12 mo PFS
Phase 2 N=341 Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
Neuroendocrine Tumors · Von Hippel-Lindau Syndrome · Hippel-Lindau Disease
Primary: Number of Lesions Detected Using the 68Gallium-DOTATATE Positron Emission Tomography (PET/Computed Tomography (CT)) Scan — 847 Number of lesions
Phase 2 N=22 Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
Gastroenteropancreatic Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 0.045 proportion of participants
Phase 2 N=160 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
Islet Cell Carcinoma · Neuroendocrine Carcinoma · Neuroendocrine Tumor
Primary: Objective Response Rate: Percentage of Participants With Best Over All Response of Complete Response or Partial Response by Central Radiology Review (Stratum 1) Based on…
Phase 2 N=123 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Phase 2 N=67 RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Neuroendocrine Carcinoma · Islet Cell Carcinoma
Primary: Progression Free Survival (PFS) — 60 Weeks
Phase 2 N=97 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer
Neuroendocrine Carcinoma
Primary: Number of Patients That Experienced a Change in Care Plans After 68GA-DOTATATE PET Scan — 19; 9; 50 participants
Phase 3 N=85 Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
Neuroendocrine Tumors
Primary: Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) — 14.3; 6.0 Months
Phase 2 N=18 A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
Neuroendocrine Tumors
Primary: Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline — 1; 11; 6 Participants
Phase 2 N=99 Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
Pancreatic Tumours · Midgut Neuroendocrine Tumours
Primary: Median Progression Free Survival (PFS) — 5.6; 8.3 months
Phase 2 N=36 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
Metastatic Gastrointestinal Carcinoid Tumor · Pulmonary Carcinoid Tumor · Recurrent Gastrointestinal Carcinoid Tumor
Primary: Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria) — 2 participants
Phase 2 N=39 Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
Neuroendocrine Carcinoma
Primary: Net Change Relative to Baseline in Tumor Blood Flow — -0.44; -0.12; -0.60; -0.40 ml/min/100gm
Phase 2 N=116 Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Well-differentiated Non-functional NET of Thoracic Origin · Well-differentiated Non-functional NET of Gastrointestinal Origin · Well-differentiated Non-functional NET of Pancreatic Origin
Primary: Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC). — 7.4; 4.8 Percentage of participants
Phase 2 N=30 Phase 2 Study of ONC201 in Neuroendocrine Tumors
Recurrent Neuroendocrine Tumor · Metastatic Neuroendocrine Tumor
Primary: Tumor Response According to RECIST Criteria — 0; 0; 0; 5 Participants
Phase 2 N=20 Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
Advanced Digestive System Neuroendocrine Neoplasm · Duodenal Neuroendocrine Tumor G1 · Functional Pancreatic Neuroendocrine Tumor
Primary: Number of Participants With Response Rate Per Response Evaluation Criteria in Solid Tumors Version 1.1 — 19 participants
Phase 2 N=41 Capecitabine and Temozolomide for Neuroendocrine Cancers
Neuroendocrine Tumors
Primary: Number of Participants With Partial Response (PR) — 9 participants
Phase 2 N=29 Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
Neuroendocrine Tumors · Carcinoid Tumors
Primary: Progression-free Survival (PFS) at One Year — 11 months
Phase 2 N=28 Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Neuroendocrine Tumors · Metastatic Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 13; 12 participants
Phase 2 N=122 Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Neuroendocrine Tumors · Carcinoid Tumors · Neuroblastoma
Primary: Number of Participants With a Change in Treatment Management Based on Findings of the Gallium Ga 68-edotreotide PET/CT Scan — 54; 6; 54 Participants
Phase 2 N=111 Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
Neuroendocrine Tumors
Primary: Best Response Rate by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 Upon Central Radiologic Assessment — 0; 0; 23; 9 Participants
Phase 4 N=50 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
NeuroEndocrine Tumours
Primary: Assessment of Clinical Symptomatic Response — 77.8; 95.5; 87.5; 22.2 Percentage of Subjects — p==0.126
Phase 2 N=13 Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
Pancreatic Neuroendocrine Tumor G1 · Pancreatic Neuroendocrine Tumor G2 · Refractory Pancreatic Neuroendocrine Carcinoma
Primary: Overall Response Rate — 0 proportion of participants
Phase 2 N=22 Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors
Neuroendocrine Tumors
Primary: Efficacy of Combination Sorafenib Plus Metronomic Cyclophosphamide in Advanced, Progressive NET, as Measured by the Objective Response Rate (ORR). — 1 Participants
Phase 2 N=20 Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: Radiographic Response (RR) — 9; 0; 9; 9 Participants
Phase 3 N=11 Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
Neuroendocrine Tumors
Primary: Sensitivity to Correctly Diagnose NET — 75; 75; 100; 75 percent of NET correctly diagnosed
Phase 3 N=302 Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
Advanced NET of GI Origin · Advanced NET of Lung Origin · Neuroendocrine Tumors
Primary: Probability of Participants Remaining Event-Free in Progression-Free Survival (PFS) Based on Central Radiology Assessment — 90.1; 74.6; 81.2; 49.1 Percent event-free…